Hims & Hers Health, Inc. announced that Kathryn Beiser will serve as its Chief Communications Officer, reporting directly to CEO Andrew Dudum. Beiser joins the company after a distinguished career that included senior roles at Eli Lilly, Discover, Kaiser Permanente, and a global leadership position in Edelman’s corporate practice.
Beiser’s background in pharmaceutical, health‑care, and public‑relations strategy positions her to guide both external and internal communications as Hims & Hers expands its domestic and international footprint. Her responsibilities will include shaping the company’s brand narrative, managing stakeholder engagement, and supporting the organization’s growth initiatives.
The appointment comes on the heels of strong financial results. In Q4 2025, Hims & Hers generated $617.8 million in revenue, up 28% year‑over‑year, and reported a full‑year 2025 revenue of $2.35 billion, a 59% increase. The subscriber base surpassed 2.5 million at year‑end, and gross margin fell to 72% from 77% in Q4 2024, reflecting the cost of scaling weight‑loss offerings and pricing adjustments.
Strategically, the company has secured a partnership with Novo Nordisk that allows it to offer branded Ozempic and Wegovy, resolving a long‑standing litigation dispute. The deal is a key driver of the company’s growth trajectory and underscores the need for a seasoned communications leader to manage the narrative around regulatory compliance, product expansion, and brand positioning in a highly competitive telehealth market.
CEO Andrew Dudum emphasized the importance of the new hire, noting that “She is the communications leader we need for this moment.” The appointment signals Hims & Hers’ intent to strengthen its reputation and stakeholder relationships as it navigates regulatory challenges and expands its service portfolio.
The addition of Kathryn Beiser aligns with Hims & Hers’ broader strategy to accelerate growth, deepen its international presence, and reinforce its brand amid evolving market dynamics. The company’s recent partnership with Novo Nordisk and its robust subscriber base provide a solid foundation for the expanded communications mandate.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.